請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89792
標題: | 瘦性非酒精性脂肪肝的血清標記物與單核苷酸多型性之探討 Biomarkers and Single Nucleotide Polymorphisms of Lean Non-alcoholic Fatty Liver Disease |
作者: | 盧佳文 Chia-Wen Lu |
指導教授: | 楊偉勛 Wei-Shiung Yang |
共同指導教授: | 黃國晉 Kuo-Chin Huang |
關鍵字: | 瘦性非酒精性脂肪肝,代謝相關性脂肪肝,胎球蛋白-A,脂聯素,瘦素,單核苷酸多型性, lean NAFLD,MAFLD,fetuin-A,adiponectin,leptin,single nucleotide polymorphism, |
出版年 : | 2023 |
學位: | 博士 |
摘要: | 背景:瘦型脂肪肝患者在脂肪肝中的比例越來越高。既是肝細胞激素又是脂肪激素的胎球蛋白-A還有脂聯素/瘦素比率和瘦性脂肪肝之間的關聯從未被研究過,此外,亞洲人群中瘦型脂肪肝的遺傳特徵也尚不清楚。
主旨:研究的目的是要探討調整中樞型肥胖和胰島素抵抗後,瘦型脂肪肝和非瘦型脂肪肝與血清胎球蛋白-A及脂聯素/瘦素比率濃度之間的關聯。此外,和瘦型對照組相比,我們旨在檢視瘦型脂肪肝的有或沒有與PNPLA3和SAMM50單核苷酸多型性的相關風險。 方法:此論文是從兩個不同的人群和數據庫中整理的三項研究。在生物標誌物和瘦型脂肪肝的研究中,納入對象是台灣北部新竹市的社區成年人。根據身體質量指數和腹部超音波的判定,將受試者分別分為瘦型對照組、瘦型脂肪肝組、單純超重/肥胖(非瘦型)組和超重/肥胖脂肪肝組。實驗室中使用酶聯免疫吸附測定法測量血清胎球蛋白-A、脂聯素和瘦素。之後,以多變量邏輯回歸分析估計在調整可能的干擾因子後,胎球蛋白-A和脂聯素/瘦素比率在不同血清濃度中患有瘦型脂肪肝的差異。我們使用接收者操作特徵曲線(以下稱ROC曲線)分析評估脂聯素/瘦素比率對瘦型脂肪肝的診斷準確度。至於單核苷酸多型性和瘦型脂肪肝相關的研究,是一項於2022年在台灣哈佛健診進行的病例對照研究。納入身體質量指數低於24 kg/m2的成年人,並藉由腹部超音波分類是否有脂肪肝。基於NHGRI-EBI網站庫料庫並使用Global Screening Array-24 v1.0 BeadChip於單核苷酸多態性的選擇,我們去除重複和不顯著的變異後,選擇了 PNPLA3 基因中的rs12483959 和SAMM50基因中的rs3761472。統計方法則使用了多重邏輯回歸模型和ROC曲線分析評估。 結果:胎球蛋白-A最高三分位數與最低三分位數血清濃度的脂肪肝勝算比為2.62(95% CI:1.72-3.98;趨勢P<0.001)。在以身體質量指數做分層分析,並調整可能的干擾因子後,胎球蛋白-A高三分位數與最低三分位數的瘦型脂肪肝勝算比為2.09(95% CI:1.09-3.98;趨勢P為0.026);與瘦型對照組相比,在調整年齡、性別、吸煙習慣、運動習慣、胰島素阻抗、和肝功能後,脂聯素/瘦素比率在瘦型脂肪肝勝算比為0.28(95%CI: 0.12-0.69)。脂聯素/瘦素比率用以診斷脂肪肝的ROC曲線為0.85(95% CI:0.82-0.88)(P<0.001)。在基因研究中,共有1,652名的瘦型對照組和602名瘦型脂肪肝患者被納入哈佛數據庫。PNPLA3 rs12483959 (OR: 3.06; 95% CI: 2.15-4.37)和SAMM50 rs3761472 (OR: 2.90; 95% CI: 2.04-4.14)的GG基因型在調整年齡、性別、身體質量指數後,得到瘦型脂肪肝風險較高。PNPLA3 rs738409和SAMM50 rs3761472檢測瘦型脂肪肝的ROC曲線下面積分別為0.859(95%CI:0.841,0.877)和0.860(95%CI:0.843,0.877)。 結論:胎球蛋白-A和脂聯素/瘦素比率可能是早期區分瘦型脂肪肝和瘦型對照組的良好生物標誌物。針對基因變異,PNPLA3 rs738409和SAMM50 rs3761472基因多態性與亞洲人群中的瘦性脂肪肝的高風險獨立相關。這些都有待進一步研究。 Background:The prevalence of lean non-alcoholic fatty liver disease (NAFLD) is on the rise, contributing to a growing proportion of liver diseases. However, the phenotypic and genetic characteristics of lean NAFLD in Asian populations have yet to be fully understood. Aims: Our study aims to investigate the correlation between serum levels of fetuin-A and the AL ratio in lean and non-lean individuals, considering their NAFLD status and adjusting for central obesity and insulin resistance. Furthermore, we intend to assess the varying risks of lean NAFLD in the presence or absence of PNPLA3 and SAMM50 variants, comparing them to lean individuals without NAFLD. Methods:Three studies were conducted using data from two distinct populations and databases. The first set of studies included community-based adults residing in Hsinchu City, Northern Taiwan. The participants were categorized into different groups based on their BMI and ultrasonographic indicators of fatty liver, including lean controls, lean NAFLD, non-lean individuals with simple overweight/obesity, and overweight/obese individuals with NAFLD. Enzyme-linked immunosorbent assay was employed to measure serum levels of fetuin-A, adiponectin, and leptin. For the study related to SNPs and lean NAFLD, it was a cohort study conducted in the HAVO Health Exam Clinic from 2022 in Taiwan. Adults with a body mass index less than 24 kg/m2 were enrolled. Fatty liver was defined by ultrasonography. The candidate gene approach employed in the study relied on the NHGRI-EBI website's library for selecting relevant genes. To analyze single nucleotide polymorphisms (SNPs), the Global Screening Array-24 v1.0 Bead Chip was utilized for the selection process. After eliminating duplicates and insignificant variants, rs12483959 in the PNPLA3 gene and rs3761472 in the SAMM50 gene were chosen for analysis. Multiple logistic regression models and ROC curves were employed in these studies. Results:The odds ratio (OR) for having NAFLD in the highest tertile compared to the lowest tertile of fetuin-A was 2.62 (95% CI: 1.72-3.98; P for trend < 0.001). When stratified by BMI and adjusted for confounding factors, the OR for having lean NAFLD in the highest versus the lowest tertile of fetuin-A was 2.09 (95% CI: 1.09-3.98; P for trend 0.026). Compared with the lean controls, the odds of having lean NAFLD for the highest versus the lowest tertile of AL ratio was 0.28(95%CI: 0.12-0.69) after adjustment. Regarding the diagnostic performance of NAFLD, incorporating the AL ratio, BMI, triglyceride levels, and AST/ALT ratio, the ROC analysis yielded an area under the curve (AUC) of 0.85 (95% CI: 0.82-0.88) for all NAFLD (P < 0.001). A total of 1,652 lean controls and 602 lean NAFLD patients were enrolled in HAVO database. After adjustment, individuals with GG genotypes of PNPLA3 rs12483959 had a higher risk of fatty liver with an odds ratio (OR) of 3.06 (95% CI: 2.15-4.37). Similarly, those with GG genotypes of SAMM50 rs3761472 also had an increased risk of fatty liver with an OR of 2.90 (95% CI: 2.04-4.14). The ROC analysis demonstrated good discriminatory ability for PNPLA3 rs738409 and SAMM50 rs3761472 in identifying lean NAFLD. The areas under the ROC curves were 0.859 (95% CI: 0.841, 0.877) for PNPLA3 rs738409 and 0.860 (95% CI: 0.843, 0.877) for SAMM50 rs3761472. Conclusions: The findings suggest that Fetuin-A and the AL ratio have the potential to serve as promising biomarkers for early differentiation between lean NAFLD patients and lean controls, irrespective of insulin resistance. Additionally, the gene variants PNPLA3 rs738409 and SAMM50 rs3761472 are independently linked to an increased risk of fatty liver in lean individuals of Asian descent. These results indicate the need for further investigation and research in this area to better understand the implications and potential clinical applications of these biomarkers and gene variants in lean NAFLD. |
URI: | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/89792 |
DOI: | 10.6342/NTU202301314 |
全文授權: | 同意授權(全球公開) |
顯示於系所單位: | 臨床醫學研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-111-2.pdf | 4 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。